These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22094831)

  • 21. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epoetins: differences and their relevance to immunogenicity.
    Haselbeck A
    Curr Med Res Opin; 2003; 19(5):430-2. PubMed ID: 13678480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an inductively coupled plasma mass spectrometry method for quantification of extracted tungsten from glass prefilled syringes used as a primary packaging for pharmaceutical and therapeutic protein products.
    Fujimori K; Lee H; Phillips J; Nashed-Samuel Y
    PDA J Pharm Sci Technol; 2013; 67(6):670-9. PubMed ID: 24265307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex.
    Deechongkit S; Aoki KH; Park SS; Kerwin BA
    J Pharm Sci; 2006 Sep; 95(9):1931-43. PubMed ID: 16850392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone.
    Katagiri D; Shibata M; Katsuki T; Masumoto S; Katsuma A; Minami E; Hoshino T; Inoue T; Tada M; Hinoshita F
    Clin Exp Nephrol; 2010 Oct; 14(5):501-5. PubMed ID: 20652821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
    Bennett CL; Cournoyer D; Carson KR; Rossert J; Luminari S; Evens AM; Locatelli F; Belknap SM; McKoy JM; Lyons EA; Kim B; Sharma R; Costello S; Toffelmire EB; Wells GA; Messner HA; Yarnold PR; Trifilio SM; Raisch DW; Kuzel TM; Nissenson A; Lim LC; Tallman MS; Casadevall N
    Blood; 2005 Nov; 106(10):3343-7. PubMed ID: 16099877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity.
    Labrenz SR; Calmann MA; Heavner GA; Tolman G
    PDA J Pharm Sci Technol; 2008; 62(3):211-23. PubMed ID: 18661870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
    Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial.
    Sörgel F; Thyroff-Friesinger U; Vetter A; Vens-Cappell B; Kinzig M
    BMC Clin Pharmacol; 2009 May; 9():10. PubMed ID: 19463151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
    Feagan BG; Wong CJ; Kirkley A; Johnston DW; Smith FC; Whitsitt P; Wheeler SL; Lau CY
    Ann Intern Med; 2000 Dec; 133(11):845-54. PubMed ID: 11103054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization and qualification of capillary zone electrophoresis method for glycoprotein isoform distribution of erythropoietin for quality control laboratory.
    Zhang J; Chakraborty U; Villalobos AP; Brown JM; Foley JP
    J Pharm Biomed Anal; 2009 Oct; 50(3):538-43. PubMed ID: 19515523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycan analysis of erythropoiesis-stimulating agents.
    Cowper B; Lavén M; Hakkarainen B; Mulugeta E
    J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations.
    Sörgel F; Thyroff-Friesinger U; Vetter A; Vens-Cappell B; Kinzig M
    Pharmacology; 2009; 83(2):122-30. PubMed ID: 19122476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.